Alpha-Glycerylphosphorylcholine and D-Panthenol Eye Drops in Patients Undergoing Cataract Surgery.
Journal
Journal of ophthalmology
ISSN: 2090-004X
Titre abrégé: J Ophthalmol
Pays: United States
ID NLM: 101524199
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
02
2022
revised:
28
03
2022
accepted:
24
05
2022
entrez:
17
6
2022
pubmed:
18
6
2022
medline:
18
6
2022
Statut:
epublish
Résumé
Cataract surgery is widespread. The surgical procedure is associated with damage to the epithelial barrier and interruption of the corneal innervation. In addition, pathological events sustain signs and symptoms that may persist for a long time. Recently, a fixed combination of alpha-glycerylphosphorylcholine and D-Panthenol (Oftassiale) has been available as eye drops. The present study investigated the effects of an Oftassiale therapy in 20 patients undergoing cataract surgery. A comparison group included 20 patients treated with topical hyaluronic acid. Standard prophylactic and anti-inflammatory treatment was prescribed to all patients. Clinical signs and symptoms were assessed over time. In vivo confocal microscopy (IVCM) was performed accordingly. Oftassiale treatment significantly reduced clinical features and improved IVCM outcomes. In addition, therapy was well-tolerated, and no clinically significant adverse events occurred. In conclusion, this study confirmed that IVCM helps assess the tunnel after cataract surgery due to its ability to provide microscopic details in vivo. Topical therapy with alpha-glycerylphosphorylcholine and D-Panthenol eye drops promoted and stabilized the reepithelialization process. This fixed combination also accelerated and modulated the repair of the corneal innervation. Moreover, this treatment was well-tolerated and safe.
Identifiants
pubmed: 35711284
doi: 10.1155/2022/1951014
pmc: PMC9197661
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1951014Informations de copyright
Copyright © 2022 Gianluca Martone et al.
Déclaration de conflit d'intérêts
The authors declare that there are no conflicts of interest.
Références
Exp Ther Med. 2016 Nov;12(5):2958-2964
pubmed: 27882101
Pharmacol Toxicol. 1994 Feb;74(2):95-100
pubmed: 8190709
Ophthalmologica. 2014;231(2):103-10
pubmed: 24296801
J Ophthalmol. 2019 Aug 19;2019:8189097
pubmed: 31531236
Int Ophthalmol. 2021 Sep;41(9):3065-3071
pubmed: 33956256
Eur J Ophthalmol. 2021 May 20;:11206721211018377
pubmed: 34011203
Klin Monbl Augenheilkd. 2021 Mar;238(3):282-287
pubmed: 32659842
Am J Ophthalmol. 2016 Oct;170:128-132
pubmed: 27521606
Eur J Ophthalmol. 2020 Nov;30(6):1301-1307
pubmed: 31902240
Front Med (Lausanne). 2021 Jul 08;8:649030
pubmed: 34307395
Biomol Concepts. 2012 Aug;3(4):345-364
pubmed: 22977648
PLoS One. 2016 Jan 15;11(1):e0146752
pubmed: 26771186
Acta Ophthalmol. 2016 Apr;94 Suppl 2:1-34
pubmed: 27111408
Graefes Arch Clin Exp Ophthalmol. 1998 Dec;236(12):922-8
pubmed: 9865623
Jpn J Ophthalmol. 2012 Mar;56(2):113-8
pubmed: 22298313
Am J Ophthalmol. 2009 Apr;147(4):725-735.e1
pubmed: 19181302
Jpn J Ophthalmol. 2020 Jul;64(4):429-436
pubmed: 32495157
Physiology (Bethesda). 2009 Aug;24:245-9
pubmed: 19675355
J Cataract Refract Surg. 2021 Nov 1;47(11):1430-1435
pubmed: 34675150
Int J Ophthalmol. 2019 Jul 18;12(7):1122-1126
pubmed: 31341802
J Cataract Refract Surg. 2019 Aug;45(8):1148-1155
pubmed: 31371007
Int J Mol Sci. 2021 Apr 29;22(9):
pubmed: 33946979
Clin Exp Ophthalmol. 2002 Jun;30(3):187-90
pubmed: 12010212
Ophthalmologica. 2013;229(1):26-31
pubmed: 23011409
Cornea. 2015 Feb;34(2):177-81
pubmed: 25474233
Ophthalmic Physiol Opt. 2008 Mar;28(2):127-34
pubmed: 18339043
Invest Ophthalmol Vis Sci. 2014 Jan 02;55(1):16-24
pubmed: 24302584
Int Ophthalmol. 2019 Jun;39(6):1345-1353
pubmed: 29926365
Ophthalmol Ther. 2021 Jun;10(2):211-223
pubmed: 33555571
Cornea. 2008 Sep;27 Suppl 1:S13-8
pubmed: 18813069
Invest Ophthalmol Vis Sci. 2004 Sep;45(9):3030-5
pubmed: 15326117